Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01233960 · ClinicalTrials.gov registry record · Phase 3
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
A Phase 3 study, sponsored by Mesoblast.
- Completed
- Registry status
- Phase 3
- Development phase
- 73
- Enrollment target
NCT01233960: Completed Phase 3 study, sponsored by Mesoblast.
NCT01233960 is a Phase 3 study that has completed, run by Mesoblast. The registered enrollment target is 73 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01233960, a Phase 3 study, has completed, sponsored by Mesoblast.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 73 participants
- Enrollment target
Study Summary
To provide open-label re-treatment with PROCHYMAL to participants enrolled in companion Protocol 603 to evaluate the safety in participants with active Crohn's disease who are resistant to standard Crohn's disease therapies.
Primary Outcome
Crohn's Disease Activity Index (CDAI) at or below 150 and increase in IBDQ
Interventions
- DRUG Prochymal®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2010-11-29 |
| Est. Completion | 2014-09-15 |
| Phase | Phase 3 |
What the finished NCT01233960 record still lists
NCT01233960 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 73 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which Prochymal® is the first listed.
NCT01233960 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01233960 about?
NCT01233960 is a clinical study titled "Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease". To provide open-label re-treatment with PROCHYMAL to participants enrolled in companion Protocol 603 to evaluate the safety in participants with active Crohn's disease who are resistant to standard Crohn's disease therapies.
What is the current status of trial NCT01233960?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 73 participants. The study started on 2010-11-29. Estimated completion is 2014-09-15.
What interventions are being tested in trial NCT01233960?
The interventions under investigation include: Prochymal® (DRUG).
Who is sponsoring clinical trial NCT01233960?
This trial is sponsored by Mesoblast, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01233960's enrollment target sits among peer trials
73 1780th of 2000 higher than 221 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI